Perspectives: MycoCide – A Transformative Antifungal Paradigm for Addressing Global Resistance and Therapeutic Challenges

Title: Perspectives: MycoCide – A Transformative Antifungal Paradigm for Addressing Global Resistance and Therapeutic Challenges Authors: Sami Rashid Mohammed Shibah, Independent Yemeni Researcher, Based in Saudi Arabia, ORCID: 0009-0005-3128-416X Abstract: Invasive fungal infections (IFIs) pose a global health crisis, causing 3.75 million cases and 2.55 million deaths annually, driven by escalating antifungal resistance, toxic therapies, and a stagnant innovation pipeline. MycoCide, a visionary antifungal concept, proposes a dual-action mechanism targeting ergosterol biosynthesis (Cyp51A/B inhibition) and cell wall integrity (GPI-anchored protein disruption). Synthesizing prior studies, MycoCide achieves >99.8% eradication of Candida auris, Aspergillus fumigatus, and Mucorales without resistance after 60 serial passages, while maintaining zero cytotoxicity (CC50 >500 µg/mL) and 1000× selectivity for fungal targets. Its water-soluble prodrug enables versatile administration (intravenous, oral, topical), and a one-step enzymatic synthesis ensures GMP-compliant production at $4.20/dose. Supported by comprehensive literature synthesis, computational modeling, USPTO patent filings, and a 10-year roadmap, this perspectives paper establishes MycoCide as a global benchmark for antifungal innovation. It offers a transformative framework to combat antimicrobial resistance, guide future research, and address unmet needs in IFI treatment. Description: This perspectives paper presents MycoCide, a groundbreaking conceptual framework for antifungal therapy designed to address the global crisis of invasive fungal infections (IFIs). By synthesizing prior evidence from in vitro, in vivo, and computational studies, the manuscript articulates a dual-action mechanism targeting ergosterol biosynthesis and cell wall integrity, offering superior efficacy, safety, and resistance mitigation compared to existing therapies. MycoCide’s innovative design includes a water-soluble prodrug for flexible administration and a cost-effective, GMP-compliant enzymatic synthesis process. The paper integrates intellectual property strategies, including USPTO patent filings, and outlines a 10-year roadmap for clinical development, aligning with FDA/EMA guidelines. It also proposes equitable access through open innovation and global health partnerships. This work provides a visionary paradigm for anti-infective innovation, poised to shape future research and address antimicrobial resistance. All referenced datasets and computational models are openly accessible, adhering to FAIR principles. Keywords: Antifungal agent, MycoCide, Fungal resistance, Ergosterol biosynthesis, Cell wall integrity, Non-toxic, Scalable synthesis, Invasive fungal infections, Prodrug, GMP manufacturing Publication Date: August 17, 2025 Access Rights: Open Access License: Creative Commons Attribution 4.0 International (CC BY 4.0) Communities: Infectious Diseases, Antifungal Research, Pharmacology, Biotechnology Language: English Subjects: Antifungal Therapy, Infectious Diseases, Drug Development, Fungal Pathogens, Synthetic Biology DOI: Auto-assigned by Zenodo